The preventable burden of pneumococcal disease in the developing world

Abstract The efficacy of pneumococcal conjugate vaccines (PCV) and their remarkable success in operational use in North America challenge us to define the burden of pneumococcal disease and the likely benefits of PCV use in developing countries. Community-based incidence studies of invasive pneumoco...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2007-03, Vol.25 (13), p.2398-2405
Main Author: Scott, J.A.G
Format: Article
Language:English
Subjects:
Allergy and Immunology
Applied microbiology
Bacteriology
Biological and medical sciences
Child, Preschool
Conjugate pneumococcal vaccine
Developing Countries
Developing country
Epidemiology
Fundamental and applied biological sciences. Psychology
Humans
Immunization
Incidence
Infant
Infant, Newborn
Invasive pneumococcal disease
LDCs
Meningitis
Microbiology
Miscellaneous
Pneumococcal Infections - epidemiology
Pneumococcal Infections - mortality
Pneumococcal Infections - prevention & control
Pneumococcal Vaccines - immunology
Pneumococcal Vaccines - therapeutic use
Pneumonia
Streptococcus pneumoniae
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vaccines, Conjugate - immunology
Vaccines, Conjugate - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The efficacy of pneumococcal conjugate vaccines (PCV) and their remarkable success in operational use in North America challenge us to define the burden of pneumococcal disease and the likely benefits of PCV use in developing countries. Community-based incidence studies of invasive pneumococcal disease (IPD) and vaccine probe analyses of efficacy trials suggest there are approximately 814,000 pneumococcal deaths in children aged
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2006.09.008